A new study published on eLife shows when T cells in the immune system find and identify targets, they release chemicals to attract more T cells, and then gather to help suppressRead More…
The high cost of cancer drugs makes it difficult for public and private health care systems to provide patients with up-to-date treatment. If this trend continues, it will be increasingly difficult forRead More…
According to the World Health Organization (WHO), cancer is the second leading cause of death in the world. In 2018 alone, 9.6 million people worldwide died of cancer, accounting for about 1/6Read More…
Most CAR-T cell therapies require targeting cancer cell-specific antigens. Now, there is a new way to target the environment around the tumor, which comes from nanobodies naturally produced by free alpacas, camelsRead More…
Great Achievements Have Been Made in Cancer Drug Listing In 2006-2017, a total of 89 oncology therapies (NTDs) were approved by the Center for Drug Evaluation and Research (CDER). The Biologics EvaluationRead More…
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…
On August 24th, a reporter was informed from Prof. Guangmei Yan research group at Zhongshan University that this group of researchers identified and gained oncolytic virus M1 synergist with accurate treatment ofRead More…
Car-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…
Chimeric antigen receptor (CAR) modified T cells (CAR-T) as a new field of adoptive immune cell therapy has become a hot spot in recent research. In 1989, Israeli scholar Gross et al.Read More…